Last Price | 0.33 | Max Price | 1.06 |
Min Price | 0.33 | 1 Year return | -35.29 |
Avg. Target | 0.00 | Expected Return | -100.00 % |
Sector | Health Care | Subsector | Biotechnology |
Sell | 0 | Rating | |
Hold | 0 | Concensus | |
Buy | 0 | ||
Annual report 2017 |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 0 | 141,925 | 0.00 % |
2020 | 0 | 170,231 | 0.00 % |
2021 | 0 | 252,886 | 0.00 % |
2022 | 0 | 238,500 | 0.00 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
Celyad's core business is the biotech sector. Over the past 10 years the global biotech companies gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.
Over the past year the company' stock lost around 62 percent. Over the past 5 years Celyad' stock lost at around 0 percent in value. Celyad's revenues between 2011 and 2015 were very volatile and moved between 0,05 million euros and 0 million euros. Celyad's net results between 2011 and 2015 were quite unstable and moved between -9,35 million euros and -29,11 million euros.
The Belgian company didn't pay out any dividends (in the past 5 years).
At the end of 2015 the Belgian company's balance sheet was worth 159,53 million euros. The total debt of the biotech company was at the end of 2015 48,06 million euros, which equals around 30,13 percent of the total balance sheet. The Belgian company's price/earnings-ratio was -10. So the market valued the stock at -10 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the Belgian stock can be seen as a value stock.
The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 403,69 million euros. At the end of 2015 the Belgian company had around 8,49 million stocks listed.
All Celyad's annual reports can be found here. More information about Celyad can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
0
|
9
|
4
|
3
|
0
|
|
Costs |
29
|
32
|
60
|
41
|
29
|
17
|
Profit |
-29
|
-24
|
-56
|
-37
|
-29
|
-17
|
Margin of profit |
0.0
|
-277.11
|
-1593.22
|
-1199.68
|
-286300.00
|
-172000.00
|
ROI |
-26.11
|
-25.98
|
-118.64
|
-67.33
|
-62.76
|
-55.50
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
111
|
91
|
48
|
56
|
46
|
31
|
Debt |
48
|
48
|
30
|
39
|
44
|
35
|
Total assets |
160
|
139
|
78
|
94
|
90
|
66
|
Solvency |
69.87
|
65.48
|
61.24
|
58.95
|
50.78
|
46.90
|
Cash |
108
|
83
|
34
|
50
|
39
|
17
|
Cashflow |
-27
|
-25
|
-44
|
-27
|
-28
|
-28
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
-0.57
|
-0.52
|
-1.48
|
-0.70
|
-0.64
|
-0.79
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
48.40
|
17.81
|
34.61
|
16.59
|
9.70
|
Eps |
-2.53
|
-5.86
|
-3.36
|
-2.29
|
-1.23
|
Price/earnings-ratio |
-19.13
|
-3.04
|
-10.30
|
-7.24
|
-0.28
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
9.76
|
4.82
|
4.65
|
3.27
|
2.22
|
Market to book |
0.20
|
0.27
|
0.13
|
0.20
|
6.54
|
Cashflow per stock |
-2.65
|
-4.50
|
-2.28
|
-2.02
|
-1.98
|
Stocks |
9
|
10
|
12
|
14
|
14
|
Market Cap |
450.78
|
175.75
|
413.32
|
231.30
|
4.74
|
Date
|
Price
|
---|---|
18 Apr 2024
|
0.33
|
17 Apr 2024
|
0.34
|
09 Apr 2024
|
0.36
|
05 Apr 2024
|
0.36
|
03 Apr 2024
|
0.34
|
30 Mar 2024
|
0.35
|
22 Mar 2024
|
0.36
|
18 Mar 2024
|
0.35
|
15 Mar 2024
|
0.36
|
12 Mar 2024
|
0.36
|
11 Mar 2024
|
0.37
|
09 Mar 2024
|
0.37
|
07 Mar 2024
|
0.37
|
01 Mar 2024
|
0.38
|
29 Feb 2024
|
0.38
|
27 Feb 2024
|
0.36
|
22 Feb 2024
|
0.36
|
21 Feb 2024
|
0.36
|
20 Feb 2024
|
0.37
|
15 Feb 2024
|
0.37
|
14 Feb 2024
|
0.36
|
13 Feb 2024
|
0.36
|
09 Feb 2024
|
0.39
|
08 Feb 2024
|
0.39
|
07 Feb 2024
|
0.38
|
06 Feb 2024
|
0.40
|
05 Feb 2024
|
0.40
|
01 Feb 2024
|
0.40
|
31 Jan 2024
|
0.40
|
30 Jan 2024
|
0.44
|